兒童再障患者及成人造血干細(xì)胞移植患者環(huán)孢素群體藥動(dòng)學(xué)研究
發(fā)布時(shí)間:2018-07-10 18:58
本文選題:環(huán)孢素 + 群體藥動(dòng)學(xué); 參考:《蘇州大學(xué)》2012年碩士論文
【摘要】:目的:通過對(duì)環(huán)孢素(cyclosporineA, CsA)在國內(nèi)兒童再障患者和成人造血干細(xì)胞移植患者的群體藥動(dòng)學(xué)特征的研究,探討不同群體藥動(dòng)學(xué)參數(shù)的影響因素,建立不同患者群體的環(huán)孢素群體藥動(dòng)學(xué)模型,為臨床環(huán)孢素個(gè)體化治療提供參考。 方法:(1)回顧性收集了94例(男49例,女45例)兒童再障患者常規(guī)監(jiān)測的194份環(huán)孢素血藥濃度和117例造血干細(xì)胞移植患者(男66例,女51例)的1571份臨床常規(guī)監(jiān)測的環(huán)孢素血藥濃度數(shù)據(jù),并詳細(xì)收集患者臨床基本資料。 (2)采用聚合酶鏈?zhǔn)椒磻?yīng)結(jié)合限制性片段長度多態(tài)性(PCR-RFLP)方法分別檢測患者CYP3A4~(*)1G、CYP3A5*3、ABCB1C1236T、ABCB1G2677T/A、ABCB1C3435T基因型,初步研究血液病患者CYP3A4、CYP3A5和ABCB1基因多態(tài)性與環(huán)孢素穩(wěn)態(tài)血藥濃度的關(guān)系。 (3)對(duì)兒童再障患者群體和成人造血干細(xì)胞移植群體分別進(jìn)行群體藥動(dòng)學(xué)研究,應(yīng)用NONMEM軟件中一級(jí)條件估計(jì)及其交互作用(FOCE-I)算法估算藥動(dòng)學(xué)參數(shù)和個(gè)體間、個(gè)體內(nèi)變異。定量考察人口學(xué)特征、生化和血常規(guī)指標(biāo)、合并用藥及CYP3A4、CYP3A5、ABCB1基因多態(tài)性等變量對(duì)環(huán)孢素藥動(dòng)學(xué)參數(shù)的影響。并采用自舉法(Bootstrap)對(duì)最終模型進(jìn)行評(píng)價(jià)。 結(jié)果:(1)在兒童再障患者和成人造血干細(xì)胞移植患者中CYP3A4~(*)1G、CYP3A5*3、ABCB1C1236T、ABCB1G2677T/A、ABCB1C3435T的等位基因頻率分別為23%、81%、71%、44%/13%、43%與27.5%、75%、68%、46%/14%、43%;在健康人群中等位基因頻率為26%、72%、71%、41%/17%、40%,患者人群等位基因頻率與健康人群基因頻率分布比較無統(tǒng)計(jì)學(xué)差異。 (2)基因多態(tài)性與環(huán)孢素穩(wěn)態(tài)血藥濃度的關(guān)系研究結(jié)果提示:兒童再障患者ABCB1C1236T純合突變型(TT型)患者劑量校正濃度(C0/D)(25.71±10.66ng·ml-1per mg·kg-1)較C攜帶者(31.73±13.82ng·ml-1per mg·kg-1)偏低(p=0.043)。CYP3A4、CYP3A5、ABCB1G2677A/T、C3435T不同基因型的C0、劑量、C0/D之間均無統(tǒng)計(jì)學(xué)意義(p0.05);成人造血干細(xì)胞移植患者中CYP3A4、CYP3A5、ABCB1不同基因型之間環(huán)孢素血藥濃度無統(tǒng)計(jì)學(xué)意義(p0.05)。 (3)NONMEM法對(duì)94例兒童再障患者環(huán)孢素?cái)?shù)據(jù)選用一房室,一級(jí)吸收和一級(jí)消除的基礎(chǔ)模型進(jìn)行擬合。環(huán)孢素最終模型群體藥動(dòng)學(xué)參數(shù)群體標(biāo)準(zhǔn)值:表觀清除率(CL/F)為29.5L·h-1(標(biāo)準(zhǔn)誤SE:1.34),表觀分布容積(V/F)為419L(SE:52.2)。CL/F和V/F的個(gè)體間變異分別為27.8%和0.14%,殘差變異為36.4%和70ng·ml-1。最終模型僅有年齡對(duì)CL/F有顯著影響。自舉法進(jìn)行內(nèi)部驗(yàn)證結(jié)果表明模型較穩(wěn)定。 (4)117例造血干細(xì)胞移植患者移植初期(≤5個(gè)月)環(huán)孢素血藥濃度數(shù)據(jù)符合一房室一級(jí)吸收和消除模型分布,藥動(dòng)學(xué)參數(shù)的群體標(biāo)準(zhǔn)值分別為清除率(CL)為14.1L·h-(1SE:1.51),分布容積(V)為980L(SE:244),生物利用度(F)為0.579(SE:0.0328)。環(huán)孢素最終模型的群體藥動(dòng)學(xué)參數(shù)的個(gè)體間變異分別為17.1%(CL),57.5%(V),31.1%(F);個(gè)體內(nèi)變異分別為29%和253ng·ml-1。最終模型顯示移植后周數(shù)(POW)、細(xì)胞色素P450酶抑制劑(INHI)抗真菌藥、紅細(xì)胞比積(HCT)、體重(WT)、甘油三酯(TG)對(duì)清除率(CL)有影響,,紅細(xì)胞比積(HCT)對(duì)分布容積有影響。CL、V和F的時(shí)間效應(yīng)參數(shù)(IOV)分別為24.3%,80.6%和28%。自舉法和交錯(cuò)確認(rèn)法驗(yàn)證模型較穩(wěn)定。 (5)造血干細(xì)胞移植患者中ABCB1C3435T基因突變型(CT/TT型)患者移植物抗宿主。℅VHD)的發(fā)生率較野生型(CC型)患者明顯升高(34.15%vs11.43%,p=0.012),其它基因多態(tài)性與GVHD的發(fā)生無統(tǒng)計(jì)學(xué)差異。 結(jié)論:(1)兒童再障患者環(huán)孢素藥動(dòng)學(xué)參數(shù)中,僅年齡對(duì)清除率有影響。成人造血干細(xì)胞移植患者環(huán)孢素藥動(dòng)學(xué)參數(shù)中,移植后周數(shù)、體重、肝藥酶抑制劑、甘油三酯、紅細(xì)胞比積對(duì)清除率有影響,紅細(xì)胞比積對(duì)分布容積有影響。 (2)本課題通過NONMEM法建立了兒童再障患者環(huán)孢素群體藥動(dòng)學(xué)模型和成人造血干細(xì)胞移植患者環(huán)孢素群體藥動(dòng)學(xué)模型,獲得個(gè)體的環(huán)孢素藥動(dòng)學(xué)參數(shù),可為兒童再障患者和成人造血干細(xì)胞移植患者在臨床上個(gè)體化使用環(huán)孢素提供依據(jù)。 (3)造血干細(xì)胞移植患者中移植物抗宿主病的發(fā)生率可能與ABCB1C3435T基因突變相關(guān)。
[Abstract]:Objective : To study the pharmacokinetics of cyclosporineA ( CsA ) in children with aplastic anemia and adult hematopoietic stem cell transplantation in China .
Methods : ( 1 ) 94 cases ( 49 males and 45 females ) were retrospectively collected , 194 samples of cyclosporine blood concentration and 117 cases of hematopoietic stem cell transplantation ( 66 males and 51 females ) received routine monitoring of cyclosporine blood concentration data , and the clinical basic data of patients were collected in detail .
( 2 ) The polymorphism of CYP3A4 , CYP3A5 * 3 , ABCB1C1236T , ABCB1G2677T / A and ABCB1C3435T were detected by polymerase chain reaction and restriction fragment length polymorphism ( PCR - RFLP ) respectively .
( 3 ) The population and adult hematopoietic stem cell transplantation population of children with aplastic anemia and adult hematopoietic stem cell transplantation were studied . The effects of demographic characteristics , biochemical and blood routine indexes , concomitant medications , and CYP3A4 , CYP3A5 and ABCB1 gene polymorphisms on the pharmacokinetic parameters of cyclosporine A were estimated quantitatively . The final model was evaluated by bootstrap method ( bootstrap ) .
Results : ( 1 ) The allele frequencies of CYP3A4 ~ ( * ) 1G , CYP3A5 * 3 , ABCB1C1236T , ABCB1G2677T / A , ABCB1C3435T were 23 % , 81 % , 71 % , 44 % / 13 % , 43 % and 27.5 % , 75 % , 68 % , 46 % / 14 % , 43 % respectively .
The frequency of allele was 26 % , 72 % , 71 % , 41 % / 17 % and 40 % in the healthy population .
( 2 ) The relationship between gene polymorphism and the steady state blood concentration of cyclosporine A showed that the dose - corrected concentration ( C0 / D ) ( 25.71 鹵 10.66ng 路 ml - 1per mg 路 kg - 1 ) of ABCB1C1236T was lower ( 31.73 鹵 13.82ng 路 ml - 1per mg 路 kg - 1 ) than that in C carrier ( 31.73 鹵 13.82ng 路 ml - 1per mg 路 kg - 1 ) ( p = 0.043 ) . There was no significant difference between the C0 , the dose and C0 / D of the different genotypes of CYP3A4 , CYP3A5 , ABCB1G2677A / T and C3435T ( p < 0.05 ) .
There was no significant difference between the concentrations of CYP3A4 銆
本文編號(hào):2114363
本文鏈接:http://sikaile.net/yixuelunwen/eklw/2114363.html
最近更新
教材專著